Transport and toxicity of 5-fluorouracil, doxorubicin, and cyclophosphamide in in vitro placental barrier model based on BeWo b30 cells

Knyazev, E N; Никулин, С. В.; Khristichenko, A. Yu.; Gerasimenko, T. N.; Kindeeva, O. V.; Петров, В. А.; Belyakova, G. A.; Maltseva, D. V.

doi:10.1007/s11172-019-2709-7

Cited by 5 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The EE% of the samples increased by 2-3% for each Let and Cyclo at the higher lipid: drug and surfactant: cholesterol molar ratios. It was proposed that the thicker bilayer formed was capable of a higher encapsulation capacity for the hydrophobic drugs [32][33][34]. The surfactant: cholesterol molar ratio significantly impacted the size of the niosomes formed, while the combined effect of the surfactant: cholesterol and lipid: drug ratio affected the EE%.…”

Section: Noisome Formulations Propertiesmentioning

confidence: 99%

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

et al. 2021

View full text Add to dashboard Cite

Breast cancer is one of the most prevalent causes of cancer mortality in women. In order to increase patient prognosis and survival rates, new technologies are urgently required to deliver therapeutics in a more effective and efficient manner. Niosome nanoparticles have been recently employed as therapeutic platforms capable of loading and carrying drugs within their core for both mono and combination therapy. Here, niosome-based nanoscale carriers were investigated as a targeted delivery system for breast cancer therapy. The platform developed consists of niosomes loaded with letrozole and cyclophosphamide (NLC) and surface-functionalized with a folic-acid-targeting moiety (NLCPFA). Drug release from the formulated particles exhibited pH-sensitive properties in which the niosome showed low and high release in physiological and cancerous conditions, respectively. The results revealed a synergic effect in cytotoxicity by co-loading letrozole and cyclophosphamide with an efficacy increment in NLCPFA use in comparison with NLC. The NLCPFA resulted in the greatest drug internalization compared to the non-targeted formulation and the free drug. Additionally, downregulation of cyclin-D, cyclin-E, MMP-2, and MMP-9 and upregulating the expression of caspase-3 and caspase-9 genes were observed more prominently in the nanoformulation (particularly for NLCPFA) compared to the free drug. This exciting data indicated that niosome-based nanocarriers containing letrozole and cyclophosphamide with controlled release could be a promising platform for drug delivery with potential in breast cancer therapy.

show abstract

Section: Noisome Formulations Propertiesmentioning

confidence: 99%

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

et al. 2021

View full text Add to dashboard Cite

show abstract

“…108 EE values of samples improved by 2-3% for each drug at the greater surfactant:cholesterol and lipid:drug molar proportions. It was suggested that the thicker bilayer could have greater encapsulation potential for hydrophobic drugs, [109][110][111] and also the presence of FA may increase the EE. Additionally, the mean size of the modified NPs was lower than that of the NLC.…”

Section: Niosomal Codelivery Of Two Drugsmentioning

confidence: 99%

Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer

Roostaee,

Derakhshani,

Mirhosseini

et al. 2024

Nanoscale

View full text Add to dashboard Cite

show abstract

“…The choriocarcinoma BeWo cell line has been used in many of these barrier models, [ 6,9,12,13 ] despite the fact that cancer cell lines generally retain most of the genetic properties of their cancer of origin. [ 14 ] BeWo cells exhibit low fusion capacities when grown to confluence and are therefore not representative of the healthy third trimester syncytium.…”

Section: Introductionmentioning

confidence: 99%

“…The cultures are subjected to perfusion on each side: trophoblast channel perfusion to model maternal blood flow and endothelial channel perfusion to mimic fetal blood flow. [9,10] However, these models do not incorporate the branched morphology reminiscent of fetal vasculature within the placenta. Further, they often utilize trophoblast cell lines which are susceptible to genetic drift over time, further distancing them from the primary cells they are meant to represent.…”

Section: Introductionmentioning

confidence: 99%

“…Further, they often utilize trophoblast cell lines which are susceptible to genetic drift over time, further distancing them from the primary cells they are meant to represent. [11] The choriocarcinoma BeWo cell line has been used in many of these barrier models, [6,9,12,13] despite the fact that cancer cell lines generally retain most of the genetic properties of their cancer of origin. [14] BeWo cells exhibit low fusion capacities when grown to confluence and are therefore not representative of the healthy third trimester syncytium.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Modeling the Progression of Placental Transport from Early‐ to Late‐Stage Pregnancy by Tuning Trophoblast Differentiation and Vascularization

Kouthouridis,

Sotra,

Khan

et al. 2023

Adv Healthcare Materials

View full text Add to dashboard Cite

The early‐stage placental barrier is characterized by a lack of fetal circulation and by a thick trophoblastic barrier, whereas the later‐stage placenta consists of vascularized chorionic villi encased in a thin, differentiated trophoblast layer, ideal for nutrient transport. In this work, predictive models of early‐ and late‐stage placental transport are created using blastocyst‐derived placental stem cells (PSCs) by modulating PSC differentiation and model vascularization. PSC differentiation results in a thinner, fused trophoblast layer, as well as an increase in human chorionic gonadotropin secretion, barrier permeability, and secretion of certain inflammatory cytokines, which are consistent with in vivo findings. Further, gene expression confirms this shift toward a differentiated trophoblast subtype. Vascularization results in a molecule type‐ and size‐dependent change in dextran and insulin permeability. These results demonstrate that trophoblast differentiation and vascularization have critical effects on placental barrier permeability and that this model can be used as a predictive measure to assess fetal toxicity of xenobiotic substances at different stages of pregnancy.

show abstract

Transport and toxicity of 5-fluorouracil, doxorubicin, and cyclophosphamide in in vitro placental barrier model based on BeWo b30 cells

Cited by 5 publications

References 27 publications

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

Co-Delivery of Letrozole and Cyclophosphamide via Folic Acid-Decorated Nanoniosomes for Breast Cancer Therapy: Synergic Effect, Augmentation of Cytotoxicity, and Apoptosis Gene Expression

Composition, preparation methods, and applications of nanoniosomes as codelivery systems: a review of emerging therapies with emphasis on cancer

Modeling the Progression of Placental Transport from Early‐ to Late‐Stage Pregnancy by Tuning Trophoblast Differentiation and Vascularization

Contact Info

Product

Resources

About